A Multicenter, Randomized, Double-blind, Phase II Study to Evaluate the Tolerability of an Induction Dose Escalation of Everolimus in Patients With Metastatic Breast Cancer

Trial Profile

A Multicenter, Randomized, Double-blind, Phase II Study to Evaluate the Tolerability of an Induction Dose Escalation of Everolimus in Patients With Metastatic Breast Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Everolimus (Primary) ; Exemestane
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms Desiree
  • Most Recent Events

    • 12 Dec 2015 Trial design presented at the 38th Annual San Antonio Breast Cancer Symposium.
    • 06 Jul 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
    • 17 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top